Scholar Rock (Nasdaq: SRRK) has unveiled encouraging Phase II data for its experimental therapy apitegromab, showing the drug ...

Australian biotech PolyActiva has brought in seasoned pharma executive Jerry St Peter as chief executive, in a leadership ...

The biopharmaceutical industry is grappling with a complex mid-year outlook in 2025, as accelerating innovation collides with ...

US biotech Actio Biosciences has raised $66 million in a series B round to support its pipeline of genetically targeted ...

US biopharma Mineralys Therapeutics has announced positive topline data from its Phase II Explore-CKD trial evaluating the ...

US pharma major AbbVie (NYSE: ABBV) today announced positive top-line results from its Phase III TEMPLE multicenter, ...

EY today released its 35th annual Biotech Beyond Borders Report. This finds that the biopharma industry is currently at an ...

US pharma firm Lisata Therapeutics (Nasdaq: LSTA) has teamed up with tech-bio company GATC Health in a strategic alliance ...

US biotech Dyne Therapeutics (Nasdaq: DYN) has revised its regulatory approach for DYNE-101, a treatment in development for ...

Draig Therapeutics, a clinical-stage company based in Cardiff, UK, and aiming to transform the treatment of neuropsychiatric ...

The UK’s National Institute for Health and Care Excellence (NICE) has today recommended Spevigo (spesolimab) for the ...

The US Food and Drug Administration has announced the Commissioner’s National Priority Voucher (CNPV) program aimed at ...